Webcast ImageWebcast
Q1 2017 BioTime, Inc. Earnings Conference Call (Live)
05/10/17 at 4:30 p.m. ET
Q1 2017 BioTime, Inc. Earnings Conference Call
Wednesday, May 10, 2017 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
December 20, 2013BioTime Reports Isolation of Novel Brain-Associated Cells From Human Embryonic Stem Cells
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 20, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine reported today the publication of a peer-reviewed scientific paper on the successful generation of human cells with markers of particular cell types in the human brain, potentially useful in the treatment of neurological diseases such as Alzheimer’s disease. The paper publ... 
Printer Friendly Version
December 04, 2013BioTime’s CEO, Dr. Michael West to Moderate Session on Mapping the Cellular Basis of Life at the 2013 World Stem Cell Summit
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 4, 2013-- BioTime, Inc. (NYSE MKT: BTX) and subsidiary, LifeMap Sciences, announced that BioTime’s CEO, Dr. Michael West will lead a session titled “From Mapping the Genome to Mapping the Embryome: The Urgent Need for an International Initiative” today at the 2013 World Stem Cell Summit in San Diego, California. The session will include world leaders in stem cell biology discussing how major advances in stem ... 
Printer Friendly Version
November 25, 2013BioTime CEO Dr. Michael West to Present at 11th Annual Commercial Translation of Regenerative Medicine Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 25, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will present at the 11th Annual Commercial Translation of Regenerative Medicine conference in London on Monday, November 25, 2013. Dr. West’s presentation titled “Strategies for the Manufacture of Highly ... 
Printer Friendly Version
November 12, 2013BioTime Announces Third Quarter 2013 Financial Results and Recent Corporate Accomplishments
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 12, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the third quarter ended September 30, 2013 and highlighted recent corporate accomplishments. Third Quarter and Recent Corporate Accomplishments BioTime’s subsidiary, Asterias Biotherapeutics, Inc., completed its ... 
Printer Friendly Version
October 28, 2013BioTime Reports Interim Results on Renevia™ Clinical Safety Trial
- Enrollment completed in first safety study of Renevia™ for dermatological applications - - Two weeks following administration, Renevia™ appears safe and well tolerated with no serious unexpected adverse events observed to date - ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 28, 2013-- BioTime, Inc. (NYSE MKT: BTX), today announced that William Tew, Ph.D., BioTime’s Chief Commercial Officer will provide an update on the development of... 
Printer Friendly Version
October 28, 2013BioTime Organizes New ESI BIO Division to Develop, Manufacture and Market the Company’s Cell-Based Research Products
Appoints Jeffrey Janus as CEO of ES Cell International Pte Ltd. ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 28, 2013-- BioTime, Inc. (NYSE MKT: BTX) today announced changes to the organization and management of its research products business. The research products business will be consolidated into a new ESI BIO Division which shall be BioTime’s primary developer, manufacturer and distributor for its growing portfolio of stem-cell-based research pr... 
Printer Friendly Version
October 28, 2013BioTime, Inc. to Provide Company Updates During Investor Day, October 28, 2013
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 28, 2013-- BioTime, Inc. (NYSE MKT: BTX) announced today that it will be holding its annual Investor Day providing company updates at the Harvard Club in New York City. The presentations will be available on the company website, www.biotimeinc.com. Thomas Okarma, M.D., Ph.D., President and CEO of Asterias Biotherapeutics Inc., will present a summary of Asterias, a new subsidiary of BioTime. Asterias r... 
Printer Friendly Version
October 04, 2013BioTime Announces Additional Products in Development Based on HyStem® Technology
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 4, 2013-- BioTime, Inc. (NYSE MKT: BTX), today announced that it has initiated the development of two new products based on its HyStem® hydrogel technology platform. The first of these new products is ReGlydeTM, a cross-linked thiol-modified hyaluronan hydrogel for the management and protection of tendon injuries following surgical repair of the digital flexor or extensor tendons of the hand. The prod... 
Printer Friendly Version
September 19, 2013BioTime Signs Exclusive Agreement with Jade Therapeutics for Ophthalmic Drug Delivery Applications of HyStem® Technology
ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 19, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the signing of an exclusive sublicense agreement with Jade Therapeutics, Inc., a Salt Lake City-based developer of ophthalmic sustained-release drug delivery platforms. This new agreement supersedes the previously announced sublicense and supply agreements and ex... 
Printer Friendly Version
August 28, 2013BioTime Receives Approval to Begin Human Clinical Trials of Renevia
ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 28, 2013-- BioTime, Inc. (NYSE MKT: BTX) today announced that it has received approval from The Spanish Agency of Medicines and Medical Devices (AEMPS) to begin human clinical trials of Renevia™, a unique biomaterial used as a delivery matrix for autologous adipose derived cells to treat the loss of subcutaneous adipose tissue (lipoatrophies) arising from trauma, surgical resection, and congenital defects and ... 
Printer Friendly Version
August 21, 2013BioTime Announces the Appointment of Lesley Stolz as Executive Vice President of Corporate Development
ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 21, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the expansion of its senior management team with the appointment of Lesley Stolz, Ph.D. as Executive Vice President, Corporate Development. Dr. Stolz has more than 18 years of life science industry experience in corporate and business development. ... 
Printer Friendly Version
August 19, 2013BioTime CEO Dr. Michael West to Give Keynote Address at the MSC 2013 Adult Stem Cell Therapy & Regenerative Medicine Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 19, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, announced that Chief Executive Officer Michael D. West, PhD will give the keynote address at the MSC 2013 Adult Stem Cell Therapy & Regenerative Medicine conference on Monday, August 19, 2013, at 12:15 p.m. EDT in Cleveland, Ohio. Dr. West will discuss the potential u... 
Printer Friendly Version
August 09, 2013BioTime Announces Second Quarter 2013 Financial Results and Recent Corporate Accomplishments
ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 9, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the second quarter ended June 30, 2013 and highlighted recent corporate accomplishments. Second Quarter and Recent Corporate Accomplishments BioTime’s shareholders approved the proposals related to the planned ... 
Printer Friendly Version
July 16, 2013BioTime CEO Dr. Michael West to Present at the Case Western Reserve University 6th Annual Regenerative Medicine Business Education Course
ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 16, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, announced that Chief Executive Officer Michael D. West, PhD will present today at the Case Western Reserve University in the meeting “The Business of Regenerative Medicine: From Stem Cells to the Market Place” in Cleveland, Ohio. Dr. West’s presentation titled “Embryomics: ... 
Printer Friendly Version
June 12, 2013BioTime Appoints Henry L. Nordhoff to Board of Directors
ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 12, 2013-- BioTime, Inc. (NYSE MKT: BTX) today announced that Henry L. Nordhoff, former CEO and Chairman of Gen-Probe Inc., has been appointed to its Board of Directors. “We are pleased to welcome an accomplished healthcare executive of Hank's caliber to BioTime's board,” said Alfred D. Kingsley, Chairman of the Board of BioTime. “Hank's 43 years of experience in the pharmaceutical business, including... 
Printer Friendly Version
June 07, 2013BioTime, Inc. Closes on $9 Million Financing
ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 7, 2013-- BioTime, Inc. (NYSE MKT: BTX) today announced that it has closed the equity financing it announced on June 3, 2013 and received gross proceeds of $9,057,966. BioTime intends to use the net proceeds from the sale of its common shares and warrants for working capital and other general corporate purposes, and may invest a portion of the proceeds in one or more of its subsidiaries, including fun... 
Printer Friendly Version
June 03, 2013BioTime, Inc. to Raise $9 Million in Registered Direct Offering
ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 3, 2013-- BioTime, Inc. (NYSE MKT: BTX) today announced that it has agreed to sell up to an aggregate of 2,180,016 common shares and 545,004 warrants to purchase common shares, in “units” with each unit consisting of one common share and one-quarter of a warrant, at an offering price of $4.155 per unit. BioTime expects to receive gross proceeds of $9,057,966.48 from the sale of the common shares and warrants. The pr... 
Printer Friendly Version
May 23, 2013BioTime Announces Results of Vote at Special Meeting of Shareholders
Shareholders approve proposals related to the planned acquisition of stem cell assets of Geron Corporation by BioTime subsidiary Asterias Biotherapeutics, Inc. ALAMEDA, Calif.--(BUSINESS WIRE)--May. 23, 2013-- BioTime, Inc. (NYSE MKT: BTX) today announced that at a Special Meeting held on May 21, 2013, its shareholders approved the proposals related to the planned acquisition of stem cell related assets from Geron Corporation by BioTime’s subs... 
Printer Friendly Version
May 20, 2013BioTime CEO Dr. Michael West to Present at USC Minisymposium: Musculoskeletal Development and Repair
ALAMEDA, Calif.--(BUSINESS WIRE)--May. 20, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will present at the USC Minisymposium: Musculoskeletal Development and Repair conference at the Keck School of Medicine, the University of Southern California, on Monday, May 20, 2013. Dr. West’s presentation titl... 
Printer Friendly Version
May 14, 2013BioTime Appoints Franklin Berger to Board of Directors
ALAMEDA, Calif.--(BUSINESS WIRE)--May. 14, 2013-- BioTime, Inc. (NYSE MKT: BTX) today announced that Franklin M. Berger, CFA, 63, has been appointed to its Board of Directors. “We are pleased to welcome a recognized biotechnology industry expert of Franklin's caliber to BioTime's Board,” said Alfred D. Kingsley, Chairman of the Board of BioTime. “Franklin adds to our Board a great deal of experience as a director of biotechnology companies, as an... 
Printer Friendly Version
May 10, 2013BioTime Announces First Quarter 2013 Financial Results and Recent Corporate Accomplishments
ALAMEDA, Calif.--(BUSINESS WIRE)--May. 10, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the first quarter ended March 31, 2013 and highlighted recent corporate accomplishments. First Quarter and Recent Corporate Accomplishments Entered into an Asset Contribution Agreement with Geron Corporation ... 
Printer Friendly Version
May 07, 2013BioTime and Subsidiary LifeMap Sciences Announce Release of Enhanced LifeMap BioReagents™ Portal Offering Additional PureStem™ Human Progenitor Cells Including Those for Diabetes Research
ALAMEDA, Calif.--(BUSINESS WIRE)--May. 7, 2013-- BioTime, Inc. (NYSE MKT: BTX) and subsidiary, LifeMap Sciences, today announced the release of the enhanced LifeMap BioReagents™ portal (http://bioreagents.lifemapsc.com/) featuring an improved user interface, product descriptions, and customer support options, as well as the addition of new PureStem™ progenitor cells to the site. These novel progenitors provide new and unique tools for researchers ... 
Printer Friendly Version
April 29, 2013BioTime Announces CFO Succession Plan
Robert W. Peabody to become CFO on May 10, 2013 ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 29, 2013-- BioTime, Inc. (NYSE MKT: BTX) announced today that its Senior Vice President and Chief Operating Officer, Robert W. Peabody, will reassume the additional role of Chief Financial Officer on May 10, 2013. BioTime’s current Chief Financial Officer, Peter S. Garcia, has resigned his position with BioTime and its subsidiaries effective May 10, 2013. Mr... 
Printer Friendly Version
April 19, 2013BioTime Enters into Worldwide License Agreement with UCLA to Develop Therapy for the Treatment of Stroke
ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 19, 2013-- BioTime, Inc. (NYSE MKT: BTX) today announced that it has entered into an exclusive license agreement with the University of California, Los Angeles (UCLA) for novel technology related to the treatment of stroke. The licensed technology, developed in the laboratories of Tom Carmichael, MD, PhD of UCLA’s Department of Neurology, at the David Geffen School of Medicine, uses one of BioTime’s HyStem® h... 
Printer Friendly Version
March 18, 2013BioTime Announces Fourth Quarter and Fiscal Year End 2012 Financial Results and Recent Corporate Accomplishments
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 18, 2013-- BioTime, Inc. (NYSE MKT: BTX), today reported financial results for the fourth quarter and year ended December 31, 2012 and highlighted its fourth quarter and recent corporate accomplishments. Fourth Quarter and Recent Highlighted Corporate Accomplishments Entered into a definitive agreement with Geron Corporation in which BioTime’s subsidiary BioTime Acquisition Corporatio... 
Printer Friendly Version
March 13, 2013BioTime to Present at 25th Annual ROTH Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 13, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Dr. Michael D. West, Chief Executive Officer, will present a corporate overview of BioTime and its subsidiaries at the 25th Annual ROTH Conference. The presentation will take place on Monday, March 18, 2013 at 5:30 p.m. PDT at The Ritz-Carlton, Laguna Ni... 
Printer Friendly Version
March 12, 2013BioTime Appoints Stephen C. Farrell to Board of Directors
ALAMEDA, Calif., Mar 12, 2013 (BUSINESS WIRE) --BioTime, Inc. (NYSE MKT: BTX) today announced that Stephen C. Farrell has been appointed to its Board of Directors. “We are pleased to welcome an experienced executive of Steve’s caliber to BioTime’s board,” said Alfred D. Kingsley, Chairman of the Board of BioTime. “Steve adds critical and highly relevant experience as a successful leader and director of healthcare companies during periods of rapid growth... 
Printer Friendly Version
March 07, 2013BioTime and Romulus Agree to Accelerate Closing Date for Second Tranche of $5 Million Financing
A total of $17.6 million in new capital raised by BioTime and its subsidiaries since October 2012 ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 7, 2013-- BioTime, Inc. (NYSE MKT: BTX) today announced it has amended its $5 million Stock and Warrant Purchase Agreement with Romulus Films, Ltd., originally signed on January 4, 2013. Through the amendment, BioTime and Romulus have agreed to accelerate the closing date for the $3 million second tra... 
Printer Friendly Version
March 04, 2013BioTime and Subsidiary LifeMap Sciences Announce Data Mining Collaboration
LifeMap Sciences’ discovery platform will be used to evaluate approximately 100 million proprietary gene expression data points relating to human embryonic stem cells generated by BioTime scientists ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 4, 2013-- BioTime, Inc. (NYSE MKT: BTX) and its bioinformatics subsidiary LifeMap Sciences, Inc. (“LifeMap”) today announced that they have entered into a definitive collaboration agreement to utilize LifeMap... 
Printer Friendly Version
January 18, 2013BioTime CEO Dr. Michael West to Present at Scale-Up and Manufacturing of Cell-Based Therapies II Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 18, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will present at the Scale-Up and Manufacturing of Cell-Based Therapies II conference in San Diego, California on Monday, January 21, 2013. Dr. West’s presentation titled “hES-Derived Clonal Embryonic Progenito... 
Printer Friendly Version
January 10, 2013BioTime Submits Protocol for Initiation of Human Clinical Trials of Renevia™ in Europe
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 10, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced it has submitted a Clinical Investigation Protocol (CIP) to European regulatory authorities for approval to initiate studies for its Renevia™ stem cell delivery platform. The Principal Investigator for the studies will be Ramon Llull, MD, and the planned tria... 
Printer Friendly Version
January 07, 2013BioTime Signs Definitive Agreement With Geron Regarding Stem Cell Assets
Investor Commits to $10 Million Financing ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 7, 2013-- BioTime, Inc. (NYSE MKT: BTX) and its recently formed subsidiary BioTime Acquisition Corporation (BAC) jointly announced today that they have entered into a definitive Asset Contribution Agreement with Geron Corporation (Nasdaq: GERN) to acquire the intellectual property, including patents and patent applications, and other assets related to Gero... 
Printer Friendly Version